Yazhou Li, Kelli L Vaughan, Yun Wang, Seong-Jin Yu, Eun-Kyung Bae, Ian A Tamargo, Katherine O Kopp, David Tweedie, Cheng-Chuan Chiang, Keith T Schmidt, Debomoy K Lahiri, Michael A Tones, Margaret M Zaleska, Barry J Hoffer, Julie A Mattison, Nigel H Greig
The endogenous incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) possess neurotrophic, neuroprotective, and anti-neuroinflammatory actions. The dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin reduces degradation of endogenous GLP-1 and GIP, and, thereby, extends the circulation of these protective peptides. The current nonhuman primate (NHP) study evaluates whether human translational sitagliptin doses can elevate systemic and central nervous system (CNS) levels of GLP-1/GIP in naive, non-lesioned NHPs, in line with our prior rodent studies that demonstrated sitagliptin efficacy in preclinical models of Parkinson's disease (PD)...
March 27, 2024: GeroScience